カレントテラピー 35-2 サンプル page 11/32
このページは カレントテラピー 35-2 サンプル の電子ブックに掲載されている11ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。
概要:
カレントテラピー 35-2 サンプル
14 Current Therapy 2017 Vol.35 No.21127)Waterhouse P, Penninger JM, Timms E, et al:Lymphoproliferativedisorders with early lethality in mice deficient inCTLA-4. Science 270:985-988, 19958)Leach DR, Krummel MF, Allison JP:Enhancement of antitumorimmunity by CTLA -4 blockade. Science 271:1734-1736, 19969)van Elsas A, Hurwitz AA, Allison JP:Combination immunotherapyof B16 melanoma using anti -cytotoxic T lymphocyte-associated antigen 4(CTLA-4)and granulocyte/macrophagecolony -stimulating factor(GM -CSF)-producingvaccines induces rejection of subcutaneous and metastatictumors accompanied by autoimmune depigmentation. J ExpMed 190:355-366, 199910)Ishida Y, Agata Y, Shibahara K, et al:Induced expression ofPD-1, a novel member of the immunoglobulin gene superfamily,upon programmed cell death. EMBO J 11:3887-3895,199211)Freeman GJ, Long AJ, Iwai Y, et al:Engagement of thePD-1 immunoinhibitory receptor by a novel B7 family memberleads to negative regulation of lymphocyte activation. JExp Med 192:1027-1034, 200012)Nishimura H, Nose M, Hiai H, et al:Development of lupuslikeautoimmune diseases by disruption of the PD-1 geneencoding an ITIM motif-carrying immunoreceptor. Immunity11:141-151, 199913)Nishimura H, Okazaki T, Tanaka Y, et al:Autoimmunedilated cardiomyopathy in PD-1 receptor-deficient mice. Science291:319-322, 200114)Latchman Y, Wood CR, Chernova T, et al:PD-L2 is a secondligand for PD-1 and inhibits T cell activation. Nat Immunol2:261-268, 200115)Iwai Y, Terawaki S, Ikegawa M, et al:PD-1 inhibits antiviralimmunity at the effector phase in the liver. J Exp Med198:39-50, 200316)Iwai Y, Ishida M, Tanaka Y, et al:Involvement of PD-L1 ontumor cells in the escape from host immune system andtumor immunotherapy by PD-L1 blockade. Proc Natl AcadSci USA 99:12293-12297, 200217)Iwai Y, Terawaki S, Honjo T:PD-1 blockade inhibits hematogenousspread of poorly immunogenic tumor cells byenhanced recruitment of effector T cells. Int Immunol 17:133-144, 200518)Phan GQ, Yang JC, Sherry RM, et al:Cancer regression andautoimmunity induced by cytotoxic T lymphocyte-associatedantigen 4 blockade in patients with metastatic melanoma.Proc Natl Acad Sci USA 100:8372-8377, 200319)Hodi FS, O’Day SJ, McDermott DF, et al:Improved survivalwith ipilimumab in patients with metastatic melanoma. NEngl J Med 363:711-723, 201020)Topalian SL, Hodi FS, Brahmer JR, et al:Safety, activity,and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 366:2443-2454, 2012